Pages that link to "Q36638387"

The following pages link to Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin to realize cancer metastasis chemoprevention (Q36638387):

Displaying 11 items.

• EMT and inflammation: inseparable actors of cancer progression. (Q33869755) (← links)
• Secretome of tumor-associated leukocytes augment epithelial-mesenchymal transition in positive lymph node breast cancer patients via activation of EGFR/Tyr845 and NF-κB/p65 signaling pathway. (Q38736999) (← links)
• Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway. (Q43987893) (← links)
• Sex-related pharmacokinetic differences and mechanisms of metapristone (RU486 metabolite). (Q47133712) (← links)
• Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention. (Q48045458) (← links)
• Suppression of the Smurf1 Expression Inhibits Tumor Progression in Gliomas (Q48254991) (← links)
• Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer (Q49469993) (← links)
• Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib. (Q64948681) (← links)
• RU486 Metabolite Inhibits CCN1/Cyr61 Secretion by MDA-MB-231-Endothelial Adhesion (Q91867253) (← links)
• Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression (Q92991830) (← links)
• The role of monoamine oxidase A in HPV-16 E7-induced epithelial-mesenchymal transition and HIF-1α protein accumulation in non-small cell lung cancer cells (Q98464620) (← links)